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Mutations in the two breast-ovarian cancer susceptibility genes,
BRCA1 and  BRCA2, account for a varying fraction of breast
cancer families in different populations (Szabo and King, 1997).
Both BRCA1 and BRCA2 mutations are scattered throughout the
large coding regions of the genes (Breast Cancer Information
Core). In admixed populations, most mutations appear uniquely in
single families only, making the mutation screening laborious and
expensive. Furthermore, there is also evidence of other predis-
posing genes (Ford et al, 1998; Kainu et al, 2000). It is, therefore,
important to find the clinical risk factors that could best predict the
presence of BRCA1 and BRCA2 mutations, so that the screening
could be directed to potential mutation carrier families. 
Several probability models for mutation detection have been
developed. These are, however, based only on BRCA1 (Berry et al,
1997; Couch et al, 1997; Shattuck-Eidens et al, 1997), focus on
specific founder mutations in the Ashkenazi population (Foulkers
et al, 1999; Hodgson et al, 1999; Hopper and Jenkins, 1999), or
require information such as penetrance estimations not available in
all populations (Berry et al, 1997; Parmigiani et al, 1998; Chang-
Claude et al, 1999). 
Here we have developed a model for predicting the presence of
a BRCA1 or BRCA2 mutation in families with 3 or more relatives
affected with breast or ovarian cancer. We also compared this
model with those of Shattuck-Eidens et al (1997) and Couch et al
(1997) originally designed for BRCA1 only. Additionally, the
frequency of BRCA1/2 mutations was studied in 295 families with
two affected family members to evaluate the feasibility of genetic
screening in families with moderate family history. 
PATIENTS AND METHODS 
The cohort studied consisted of 148 families with 3 or more 1st or 2nd
degree relatives affected with breast or ovarian cancer. The families
were identified by patient interviews, and full pedigrees were
constructed with the confirmation of all genealogy data through the
Finnish population registration as well as diagnostic data through
hospital records and/or Finnish Cancer Registry as previously
described (Vehmanen et al, 1997a,b; Eerola et al, 2000). Additionally,
295 breast cancer cases with one 1st degree relative affected with
breast or ovarian cancer and identified in the patient cohorts described
in Eerola et al (2000) were also studied. In the following, these are
called small families. The family history of these cases was based on
information reported by the index patient. All patients participating in
the study signed an informed consent before the blood sample for the
genetic analysis was taken. This study has been approved by the
Ethical Committees of Departments of Obstetrics and Gynaecology,
and Oncology, HUCH, and appropriate permissions were obtained
from the Ministry of Social Affairs and Health in Finland. 
The mutations identified by a complete mutation analysis of the
whole coding sequences and exon/intron boundaries of the genes
in 95 of these families have been previously reported (Vehmanen
et al, 1997a,b). For 53 other families, all previously reported 18
Finnish BRCA1 and BRCA2 mutations (Vehmanen et al, 1997a,b;
Huusko et al, 1998; Sarantaus et al, 2000), and one recently
discovered new BRCA1 mutation (3264 delT) were analysed by
allele-specific oligonucleotide (ASO) (Friedman et al, 1995)
hybridization or restriction fragment length polymorphism
(RFLP). The RFLP analyses were designed such that incomplete
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digestion would lead to a false positive hence minimizing the
possibility of a false negative result. Sequences of the PCR
primers and ASO probes, as well as the enzymes used for diges-
tions are available upon request. Protein truncation test (PTT)
(Hogervorst et al, 1995; Håkansson et al, 1997) of BRCA1 exon 11
and BRCA2 exons 10 and 11 was also used to search for new
mutations in 36 families with an ovarian cancer case or a breast
cancer patient diagnosed below 50 years. All positive mutation
detection results were confirmed by direct sequencing using an
ABI PRISM 310 Genetic Analyser and Dye Terminator Cycle
Sequencing Ready Reaction Kit according to the manufacturer’s
instructions (PE Applied Biosystems, Foster City, CA, USA). 
For 295 small breast cancer families ASO and RFLP analyses
were used to screen all known Finnish mutations, and direct
sequencing was used to confirm the positive screening results. In
previous studies, 11 recurrent founder mutations have been found
to account for vast majority (84%) of all Finnish BRCA1 and
BRCA2 families (Vehmanen et al, 1997a,b; Huusko et al, 1998).
Therefore, screening of the known mutations was used to evaluate
the feasibility of screening of the BRCA1 and BRCA2 genes in
these families. 
Statistical analysis 
Associations between specific familial characteristics (presented
in Table 1) and the presence of a BRCA1 or BRCA2 germline
mutation were studied by univariate and multivariate analyses. For
univariate analysis, Mann-Whitney and Fisher’s exact tests (SPSS
8.0 for Windows) were used. Variables that were predictive of a
mutation in a univariate analysis were used in a multivariate
analysis (stepwise backward logistic regression, 99%), and based
on that a logistic probability model for harbouring a deleterious
mutation was devised. 
The models by Couch et al (1997) and Shattuck-Eidens et al
(1997), previously designed for estimating mutation probability in
the  BRCA1 gene, were also tested in the 148 families and
compared to the model developed here for their applicability to
distinguish carrier families with mutations in either gene. 
RESULTS AND DISCUSSION 
Mutations identified 
A total of 29 germline mutations was found in 148 families
(19.6%), 16 in BRCA1 (10.8%) and 13 in BRCA2 (8.8%). In
addition to previously known Finnish mutations, two new protein
truncating mutations were identified (BRCA1, 1806 C ® T and
BRCA2, 5797 G ® T). Both of these mutations were subsequently
found also in other study cohorts (Syrjäkoski et al, 2000; Sarantaus
L, personal communication) making the total number of recurrent
mutations in Finland now 13. Altogether, 24 (86%) of the
mutation-positive patients carried one of the recurrent mutations,
and 5 patients unique mutations not found in other families so far
in Finland. 
Factors associated with positive mutation status 
Several factors were associated with the presence of germline
BRCA1 or BRCA2 mutations in the univariate analysis (Table 1).
In the multivariate analysis, only two variables were still signifi-
cant: the number of ovarian cancer cases in a family (P < 0.00005)
and the age at diagnosis of the youngest breast cancer patient (P =
0.0007). The presence of breast and ovarian cancer in the same
patient was not significant in multivariate analysis, probably
because it is closely associated with ovarian cancer cases overall.
Bilateral breast cancer, another factor that has been correlated with
a positive mutation status by for example Shattuck-Eidens et al
(1997) and Ligtenberg et al (1999), was not significant in
univariate analysis and, therefore, not included in further analysis. 
Families carrying a mutation in either BRCA1 or BRCA2 were
also analysed separately (data not shown). The results were similar
for both genes except for the number of breast cancer patients that
was associated with a BRCA2 mutation status in the univariate
analysis. In the multivariate analysis the same variables were
significant for both genes and, therefore, one common model
could be used for distinguishing all mutation carriers. Early age of
breast cancer onset as well as the presence of ovarian cancer in a
family are thus highly characteristic for Finnish BRCA2 families
also. It is of interest to note that only one of the BRCA2 mutations
in this study was in the OCCR region where a higher risk of
ovarian cancer, relative to breast cancer, has been suggested
(Gayther et al, 1997; Ford et al, 1998). 
Probability of identification of a mutation in the family 
Based on the results from the multivariate analysis, a probability
model for harbouring a deleterious mutation was devised, and can
be written in the form of: 
Table 1 Variables tested and the associations found in univariate analysis 
BRCA1 / BRCA2 non-BRCA1/2 P value in univariate analysis 
Variables concerning the number of breast and ovarian cancer cases Mean number of cancer cases 
Mean number of breast cancer cases in a family 3.5 3.8 0.304 
Mean number of ovarian cancer cases in a family 1.4 0.2 <0.0005 
Mean number of bilateral breast cancer cases in a family 0.5 0.3 0.292 
Variables concerning the age at diagnosis Age in years 
Age at diagnosis of the index case 41.3 51.4 <0.0005 
Age at diagnosis of the youngest breast cancer patient 38.5 46.0 <0.0005 
Age at diagnosis of the youngest ovarian cancer patient 52.0 59.7 0.056 
Mean age at diagnosis of the breast cancer cases 47.6 56.4 <0.0005 
Variables concerning the presence of different cancer types  Proportion 
Presence of ovarian cancer in a family 79% (23/29) 20% (24/119) <0.0005 
Presence of breast and ovarian cancer in the same individual  34% (10/29) 2.5% (3/119) <0.0005 
Presence of bilateral breast cancer in a family 31% (9/29) 24% (29/119) 0.482 
Presence of prostate cancer in a family 24% (7/29) 15% (18/119) 0.272 p=e L / (1 + eL)
and L can be calculated from the equation L = 2.87 + (–0.14) ´ V1
+ 2.11 ´ V2 where 2.87 is a constant and –0.14 and 2.11 are the
coefficients received from the regression analysis, V1 is the age of
the youngest breast cancer patient in a family, and V2 is the
number of ovarian cancer cases in a family. 
Among the 148 study families, 97% (28/29) of the mutation
carrier families obtained a probability greater than an arbitrary cut
off value of 10%. The mean probability was 55% for mutation-
positive families and 11% for mutation-negative families.
Altogether, out of 148 families 63 (43%) obtained probabilities
over 10% and among these, 28 (44%) were mutation carrier fam-
ilies. Thus by using this model, mutation screening could be
directed to a significantly smaller proportion of families. 
Similar results were obtained also with the models of Shattuck-
Eidens et al (1997) and Couch et al (1997) originally designed for
BRCA1 (Table 2). Thus these models distinguish also BRCA2
mutation carrier families very efficiently. The one mutation-
positive family missed in all 3 models has 3 affected breast cancer
patients all diagnosed at later age. The proportion of mutations
found is higher in the model developed in this study since it has
been designed particularly for this study cohort, and the deter-
mination of sensitivity as well as specificity of this model requires
analysis of a separate test population. The model here was also
designed to estimate the carrier probability of a family with 3 or
more affected cases, and therefore it could not be extrapolated to
cases with a less profound family history. 
Mutation frequencies in families with defined family
history of cancer 
All families classified by the family history of breast and ovarian
cancer as well as age of breast cancer onset (below 40 years) are
presented in Table 3. By analysing mutation-positive and -negative
families, initially chosen by the criterion of at least 3 breast or
ovarian cancer patients among 1st or 2nd degree relatives, we
noted that mutation carrier families could be identified by a simple
criterion of a breast cancer case diagnosed before the age of 40 or
an ovarian cancer case in the family. Altogether, 80/148 (54% of
all) families fulfilled this criterion, and among these, 28/29 (97%)
of the mutations could be found. This simple criterion alone could
thus be used as a rough estimation of a high likelihood of carrying
a mutation in such families. 
No mutations were found in 21 families with 4 or more cases of
breast but no ovarian cancer or young breast cancer patient (diag-
nosis below 40 years). This is in agreement with our results from
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Table 2 Comparison of the different probability models 
Shattuck-Eidens Couch This study 
Mutation positive families identified (total) 27/29 (93%) 25/29 (86%) 28/29 (97%) 
BRCA1-positive families identified 15/16 (94%) 14/16 (88%) 16/16 (100%) 
BRCA2-positive families identified 12/13 (92%) 10/13 (77%) 12/13 (92%) 
Number of families with the probability >10% 67/148 (45%) 42/148 (28%) 63/148 (43%) 
Mean probability for BRCA 1/2-carriers 53% 41% 55% 
Mean probability for BRCA 1-carriers 50% 41% 59% 
Mean probability for BRCA 2-carriers 55% 40% 50% 
Mean probability for non-BRCA 1/2-carriers 12% 7% 11% 
Table 3 Family history of breast and ovarian cancer of the families studied 
Total number of families Number of mutations 
BRCA1 BRCA2 non–BRCA1/2 Mutation % 
3 affected 74 6 2 66 10.8% 
Only breast, none under 40 47 0 1 46 2.1% 
Only breast, some under 40 15 1 0 14 6.7% 
Breast and ovarian, none under 40 9 3 0 6  33.3% 
Breast and ovarian, some under 40 3 2 1 0  100% 
4 affected 35 5 3 27 22.9% 
Only breast, none under 40 15 0 0 15 0% 
Only breast, some under 40 7 1 0 6 14.3% 
Breast and ovarian, none under 40 11 3 1 7  36.4% 
Breast and ovarian, some under 40 3 1 2 0 100% 
>5 affected 39 5 8 26 33.3% 
Only breast, none under 40 6 0 0 6 0% 
Only breast, some under 40 10 0 2 8 20.0% 
Breast and ovarian, none under 40 9 1 0 8 11.1% 
Breast and ovarian, some under 40 14 4 6 4  71.4% 
Total 148 16 13 119 19.6% 
Only breast, none under 40 68 0 1 67 1.5% 
Only breast, some under 40 32 2 2 28 12.5% 
Breast and ovarian, none under 40 28 7 1 20  28.6% 
Breast and ovarian, some under 40 20 7 9 4  80.0% 1035 unselected breast cancer patients, where all 15 cases with
heavy breast cancer family history were also mutation negative
(Syrjäkoski et al, 2000). Other, yet unknown susceptibility genes
remain to be identified and may account for a large proportion of
breast cancer families (Rebbeck et al, 1996; Serova et al, 1997;
Vehmanen et al, 1997b; Ford et al, 1998; Kainu et al, 2000). 
In 295 breast cancer cases with one affected 1st degree relative
only one mutation (BRCA2, 7708 C ® T) was found giving the
mutation frequency of 0.3%. In this family the index patient was
diagnosed at the age of 37, and her mother had died of breast
cancer at the age of 40. Ovarian cancer or a young breast cancer
patient diagnosed under 40 years was present in 39 families, but
among these only this one mutation was found (2.6%). This
suggests that mutation screening in families with only 2 affected
cases is not feasible in Finland. In contrast, Goelen et al (1999)
reported that BRCA1/2 mutation testing can be done with reason-
able efficiency in the Belgian population when there are 2 symptom-
atic family members. Prevalent founder mutations account for a
large fraction of breast cancer families in Belgium (Peelen et al,
1997; Goelen et al, 1999), while BRCA1 and BRCA2 mutations are
more rare in the Finnish population (Vehmanen et al, 1997a,b;
Huusko et al, 1998). Also in studies of patients with early onset
breast cancer, only a small proportion of familial risk of breast
cancer has been attributed to these two genes, and the majority
appears to be due to other genes (Peto et al, 1999). 
CONCLUDING REMARKS 
As the screening of both BRCA1 and BRCA2 is very laborious and
expensive, and genetic testing may be emotionally very stressful
for the families, the potential mutation carrier families should be
recognized as efficiently as possible to avoid unnecessary analyses
of non-carriers. Studies of breast cancer patients have indicated
that it may be difficult to define mutation screening criteria among
women with minimal or no family history (Malone et al, 1998).
Furthermore, the carrier risks associated with the mutations may
be highly variable, and population-based risk estimates have indi-
cated much lower cancer risks than those obtained from multiple-
case families and, therefore, lower predictive value of cancer 
for a positive mutation test result (Struewing et al, 1997; Fodor 
et al, 1998; Thorlacius et al, 1998; Hopper et al, 1999; Warner et al,
1999). Accordingly, genetic screening would be of greatest benefit
in families with high cancer risk, i.e. strong family history (Fodor
et al, 1998), and a high probability of harbouring a BRCA1 or
BRCA2 mutation. For this study, we chose families with a defined
family history, and developed a model by which likelihood of
carrying a BRCA1 or BRCA2 mutation can be estimated for each
family separately. It should be a useful tool in genetic counselling
and focusing the mutation analyses, and increasing thus the cost-
effectiveness of the genetic screening. 
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